title: Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries.
abstract: BACKGROUND
  The goal of this study was to evaluate the efficacy of a nanoporous CREG-eluting stent (CREGES) in inhibiting neointimal formation in a porcine coronary model.
  
  
  METHODS
  In vitro proliferation assays were performed using isolated human endothelial and smooth muscle cells to investigate the cell-specific pharmacokinetic effects of CREG and sirolimus. We implanted CREGES, control sirolimus-eluting stents (SES) or bare metal stents (BMS) into pig coronary arteries. Histology and immunohistochemistry were performed to assess the efficacy of CREGES in inhibiting neointimal formation.
  
  
  RESULTS
  CREG and sirolimus inhibited in vitro vascular smooth muscle cell proliferation to a similar degree. Interestingly, human endothelial cell proliferation was only significantly inhibited by sirolimus and was increased by CREG. CREGES attenuated neointimal formation after 4 weeks in porcine coronary model compared with BMS. No differences were found in the injury and inflammation scores among the groups. Scanning electron microscopy and CD31 staining by immunohistochemistry demonstrated an accelerated reendothelialization in the CREGES group compared with the SES or BMS control groups.
  
  
  CONCLUSIONS
  The current study suggests that CREGES reduces neointimal formation, promotes reendothelialization in porcine coronary stent model.
authors.affiliation: Department of Cardiology, Institute of Cardiovascular Research of People's Liberation Army, Shenyang Northern Hospital, Shenyang, Liaoning, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Deng
authors.forename: Yaling
authors.initials: Y
authors.lastname: Han
authors.forename: Mingyu
authors.initials: M
authors.lastname: Sun
authors.forename: Jie
authors.initials: J
authors.lastname: Tao
authors.forename: Chenghui
authors.initials: C
authors.lastname: Yan
authors.forename: Jian
authors.initials: J
authors.lastname: Kang
authors.forename: Shaohua
authors.initials: S
authors.lastname: Li
mesh_terms: D000327:Adsorption; D000818:Animals; D049109:Cell Proliferation; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology; D054855:Drug-Eluting Stents; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects / Q000502:physiology; D006801:Humans; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000502:physiology; D058426:Neointima / Q000517:prevention & control*; D010982:Platelet-Derived Growth Factor / Q000502:physiology; D012097:Repressor Proteins / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage / Q000494:pharmacology; D034421:Sus scrofa
chemical_list: C114068:CREG1 protein, human; D010982:Platelet-Derived Growth Factor; D012097:Repressor Proteins; D020123:Sirolimus